Ekta Batra is a Senior Editor Pharma & Health at CNBC-TV18. With nearly 14 years of experience, she specializes in pharmaceuticals and healthcare, covering key trends, issues, and daily news related to the sector. Ekta is also the host of the acclaimed podcast ‘TheMedicineBox’ and has been recognized as one of the 40 most Promising English Journalists Under 40 by ENBA in 2021, with her work featured in CNBC-TV18, Environmental Health News, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Ekta Batra's focus is on the Indian healthcare and pharmaceutical industry, particularly covering investment analysis and data-driven insights. She appears to be interested in articles that involve mergers, market trends, drug development, stocks, and other related topics within the pharmaceutical industry.
Given Ekta's emphasis on citing data and investment analysis, she would likely respond well to pitches from experts who can provide unique insights into market trends or specific data-backed analyses within the Indian pharmaceutical sector. Additionally, sources with expertise in mergers and acquisitions or stock recommendations may also find success when reaching out to her.
As Ekta's geographic focus is national (India), it’s important for pitches to keep this local perspective in mind when providing relevant information or expert commentary about the Indian pharmaceutical landscape.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ekta Batra, Vinnii Motiwala
SIS expects to sustain its long-term organic growth guidance of 15-20% despite a strong first quarter aided by the AP Securitas acquisition. CEO Dhiraj Singh said margin improvement is expected over the next few quarters through contract repricing, while synergies from acquisitions and technology investments are likely to support profitability over the longer term.
By: Ekta Batra, Vinnii Motiwala, Sonal Bhutra
Ravi Chawla, MD & CEO of Gulf Oil Lubricants India, said the company is maintaining a 12-14% margin band despite higher costs and plans to increase capacity at both plants by 70%.
By: Ekta Batra, Vivek Dubey
Indians taking weight loss drugs are eating smaller portions, choosing softer foods and focusing more on hydration, while household grocery buying hab...
By: Ekta Batra
TCS' acquisition of MHP reflects a wider shift among Indian IT companies towards acquisitions and AI-led investments, according to Sowilo Investment Managers' Sandip Agarwal. He expects more deals over the next three to five years, sees the transaction becoming EPS accretive over time, and believes AI adoption will support the sector's growth.
By: Nigel D Souza, Ekta Batra
Parthiv Jhonsa, Vice President, Anand Rathi Institutional Equities, remains bullish on Hindustan Copper, seeing EBITDA rising to ₹2,500 crore in FY27 and potentially ₹4,800-5,000 crore over the next five to six years.
By: Ekta Batra, Vinnii Motiwala
PDS expects its partnership with Busana Apparel Group to increase EBIT margins from about 7% to 11% over the next two years while boosting revenue from existing manufacturing capacity by 20-25%, Group CEO Sanjay Jain told CNBC-TV18. The company also aims to increase the US contribution to revenue to 30% over the next two to three years as order book growth supports execution.
By: Ekta Batra, Juviraj Anchil
Metropolis Healthcare in its investors call said it expects its earnings before interest tax depreciation and amortisation (EBITDA) margin to improve by 100 to 150 bps from 25.2% in the first quarter.
By: Shloka Badkar, Ekta Batra
At the end of the June quarter, promoter entities held 31.17% stake in Fortis Healthcare while public shareholders held 69%. Promoter group and IHH healthcare arm Northern TK Venture Pte Ltd held 31.17% stake in Fortis Healthcare at the end of the first quarter, as per data available on the exchanges.
By: Ekta Batra
Rasonque, a new pancreatic cancer drug, has been approved in the US. It targets the KRAS mutation, extending patient lives and shrinking tumors. The drug costs about $39,800 per month.
By: Ekta Batra, Sonal Bhutra
Abhishek Agarwal, whole-time director and CEO of Purple Style Labs, said the company has always been focused on growth and plans to deploy the IPO proceeds over the next three years and three months towards lease liabilities for its stores in India.
